Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-77c89778f8-gvh9x Total loading time: 0 Render date: 2024-07-17T16:33:20.619Z Has data issue: false hasContentIssue false

Chapter 21 - Luteinizing Hormone Supplementation during Ovarian Stimulation

from Section 4 - Non-conventional Forms Used during Ovarian Stimulation

Published online by Cambridge University Press:  14 April 2022

By
Ioannis E. Messinis ,
Christina I. Messini ,
George Anifandis  and
Alexandros Daponte
Edited by
Mohamed Aboulghar  and
Botros Rizk
Mohamed Aboulghar
Affiliation:
University of Cairo IVF Centre
Botros Rizk
Affiliation:
University of South Alabama
Get access

Summary

Folliculogenesis in humans is a long process. It has become clear that there are two main time points in follicular development, the “initial recruitment” that takes place at the stage of primordial follicles and the “cyclic recruitment” at the stage of small antral follicles [1]. In humans, the initial recruitment is gonadotropin independent, while cyclic recruitment is entirely dependent on the action of both follicle-stimulating hormone (FSH) and luteinizing hormone (LH) [2]. Locally produced substances affect the action of gonadotrophins on follicle maturation. The balanced effect of FSH and LH in the normal menstrual cycle ensures the selection of a single follicle.

Type
Chapter
Information
Ovarian Stimulation , pp. 199 - 207
Publisher: Cambridge University Press
Print publication year: 2022

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Gougeon, A. Dynamics of follicular growth in the human: a model from preliminary results. Hum Reprod 1986;1:81–87.CrossRefGoogle Scholar
Messinis, IE, Messini, CI, Dafopoulos, K. The role of gonadotropins in the follicular phase. Ann N Y Acad Sci 2010;1205:5–11.Google Scholar
Messinis, IE. Mechanisms of follicular development: the role of gonadotrophins. In: Rizk, B, Garcia-Velasco, J, Sallam, H, Makrigiannakis, A., eds. Infertility and Assisted Reproduction. Cambridge: Cambridge University Press; 2008:3–24.Google Scholar
van Santbrink, EJ, Hop, WC, van Dessel, TJ, de Jong, FH, Fauser, BC. Decremental follicle-stimulating hormone and dominant follicle development during the normal menstrual cycle. Fertil Steril 1995;64:37–43.CrossRefGoogle ScholarPubMed
Mihm, M, Baker, PJ, Ireland, JL, et al. Molecular evidence that growth of dominant follicles involves a reduction in follicle-stimulating hormone dependence and an increase in luteinizing hormone dependence in cattle. Biol Reprod 2006;74:1051–1059.CrossRefGoogle Scholar
Hillier, SG. Gonadotropic control of ovarian follicular growth and development. Mol Cell Endocrinol 2001;179:39–46.Google Scholar
Garg, D, Tal, R. The role of AMH in the pathophysiology of polycystic ovarian syndrome. Reprod Biomed Online 2016;33:15–28.Google Scholar
Erickson, GF, Shimasaki, S. The role of the oocyte in folliculogenesis. Trends Endocrinol Metab 2000;11:193–198.Google Scholar
Messinis, IE, Templeton, AA. Pituitary response to exogenous LHRH in superovulated women. J Reprod Fertil 1989;87:633–639.Google Scholar
Messinis, IE, Milingos, S, Zikopoulos, K, et al. Luteinizing hormone response to gonadotrophin-releasing hormone in normal women undergoing ovulation induction with urinary or recombinant follicle stimulating hormone. Hum Reprod 1998;13:2415–2420.CrossRefGoogle ScholarPubMed
Messinis, IE, Messini, CI, Anifandis, G, Garas, A, Daponte, A. Gonadotropin surge-attenuating factor: a nonsteroidal ovarian hormone controlling GnRH-induced LH secretion in the normal menstrual cycle. Vitam Horm 2018;107:263–286.Google Scholar
Cedrin-Durnerin, I, Bidart, JM, Robert, P, et al. Consequences on gonadotrophin secretion of an early discontinuation of gonadotrophin-releasing hormone agonist administration in short-term protocol for in-vitro fertilization. Hum Reprod 2000;15:1009–1014.Google Scholar
Borm, G, Mannaerts, B. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group. Hum Reprod 2000;15:1490–1498.Google Scholar
Felberbaum, RE, Albano, C, Ludwig, M, et al. Ovarian stimulation for assisted reproduction with HMG and concomitant midcycle administration of the GnRH antagonist cetrorelix according to the multiple dose protocol: a prospective uncontrolled phase III study. Hum Reprod 2000;15:1015–1020.Google Scholar
Propst, AM, Hill, MJ, Bates, GW, et al. Low-dose human chorionic gonadotropin may improve in vitro fertilization cycle outcomes in patients with low luteinizing hormone levels after gonadotropin-releasing hormone antagonist administration. Fertil Steril 2011;96:898–904.Google Scholar
Fleming, R, Lloyd, F, Herbert, M, et al. Effects of profound suppression of luteinizing hormone during ovarian stimulation on follicular activity, oocyte and embryo function in cycles stimulated with purified follicle stimulating hormone. Hum Reprod 1998;13:1788–1792.Google Scholar
Bosch, E, Vidal, C, Labarta, E, et al. Highly purified hMG versus recombinant FSH in ovarian hyperstimulation with GnRH antagonists: a randomized study. Hum Reprod 2008;23:2346–2351.Google Scholar
van Wely, M, Kwan, I, Burt, AL, et al. Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. Cochrane Database Syst Rev 2011;2:CD005354.Google Scholar
Tarlatzis, B, Tavmergen, E, Szamatowicz, M, et al. The use of recombinant human LH (lutropin alfa) in the late stimulation phase of assisted reproduction cycles: a double-blind, randomized, prospective study. Hum Reprod 2006;21:90–94.CrossRefGoogle ScholarPubMed
NyboeAndersen, A, Humaidan, P, Fried, G, et al.; Nordic LH study group. Recombinant LH supplementation to recombinant FSH during the final days of controlled ovarian stimulation for in vitro fertilization. A multicentre, prospective, randomized, controlled trial. Hum Reprod 2008;23:427–434.Google Scholar
Franco, JG Jr., Baruffi, RL, Oliveira, JB, et al. Effects of recombinant LH supplementation to recombinant FSH during induced ovarian stimulation in the GnRH-agonist protocol: a matched case-control study. Reprod Biol Endocrinol 2009;7:58.Google Scholar
Kolibianakis, EM, Kalogeropoulou, L, Griesinger, G, et al. Among patients treated with FSH and GnRH analogues for in vitro fertilization, is the addition of recombinant LH associated with the probability of live birth? A systematic review and meta-analysis. Hum Reprod Update 2007;13:445–452.Google Scholar
Al-Inany, HG, Abou-Setta, AM, Aboulghar, MA, Mansour, RT, Serour, GI. Highly purified hMG achieves better pregnancy rates in IVF cycles but not ICSI cycles compared with recombinant FSH: a meta-analysis. Gynecol Endocrinol 2009;25:372–378.Google Scholar
Mochtar, MH, Danhof, NA, Ayeleke, RO, Van der Veen, F, van Wely, M. Recombinant luteinizing hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for ovarian stimulation in IVF/ICSI cycles. Cochrane Database Syst Rev 2017;5:CD005070.Google Scholar
Thuesen, LL, Loft, A, Egeberg, AN, et al. A randomized controlled dose-response pilot study of addition of hCG to recombinant FSH during controlled ovarian stimulation for in vitro fertilization. Hum Reprod 2012;27:3074–3084.Google Scholar
Requena, A, Cruz, M, Ruiz, FJ, García-Velasco, JA. Endocrine profile following stimulation with recombinant follicle stimulating hormone and luteinizing hormone versus highly purified human menopausal gonadotropin. Reprod Biol Endocrinol 2014;12:10.CrossRefGoogle ScholarPubMed
Messinis, IE, Templeton, AA. Disparate effects of endogenous and exogenous oestradiol on luteal phase function in women. J Reprod Fertil 1987;79:549–554.Google Scholar
Martins, WP, Ferriani, RA, Navarro, PA, Nastri, CO. GnRH agonist during luteal phase in women undergoing assisted reproductive techniques: systematic review and meta-analysis of randomized controlled trials. Ultrasound Obstet Gynecol 2016;47:144–151.Google Scholar
van der Linden, M, Buckingham, K, Farquhar, C, Kremer, JA, Metwally, M. Luteal phase support for assisted reproduction cycles. Cochrane Database Syst Rev 2015;7:CD009154.Google Scholar
Mochtar, MH, Van der Veen, F, Ziech, M, van Wely, M. Recombinant luteinizing hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles. Cochrane Database Syst Rev 2007;2:CD005070.Google Scholar
Matorras, R, Prieto, B, Exposito, A, et al. Mid-follicular LH supplementation in women aged 35-39 years undergoing ICSI cycles: a randomized controlled study. Reprod Biomed Online 2009;19:879–887.CrossRefGoogle ScholarPubMed
Bosch, E, Labarta, E, Crespo, J, et al. Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis. Fertil Steril 2011;95:1031–1036.CrossRefGoogle ScholarPubMed
König, TE, van der Houwen, LE, Overbeek, A, et al. Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years or older undergoing IVF/ICSI: a randomized controlled multicentre study. Hum Reprod 2013;28:2804–2812.Google Scholar
Hill, MJ, Levens, ED, Levy, G, et al. The use of recombinant luteinizing hormone in patients undergoing assisted reproductive techniques with advanced reproductive age: a systematic review and meta-analysis. Fertil Steril 2012;97:1108.e1–1114.e1.Google Scholar
Lehert, P, Kolibianakis, EM, Venetis, CA, et al. Recombinant human follicle-stimulating hormone (r-hFSH) plus recombinant luteinizing hormone versus r-hFSH alone for ovarian stimulation during assisted reproductive technology: systematic review and meta-analysis. Reprod Biol Endocrinol 2014;12:17.Google Scholar
Humaidan, P, Chin, W, Rogoff, D, et al.; ESPART Study Investigators. Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders. Hum Reprod 2017;32:544–555.Google Scholar
Revelli, A, Chiado’, A, Guidetti, D, et al. Outcome of in vitro fertilization in patients with proven poor ovarian responsiveness after early vs. mid-follicular LH exposure: a prospective, randomized, controlled study. J Assist Reprod Genet 2012;29:869–875.Google Scholar
Messinis, IE, Bergh, T, Wide, L. The importance of human chorionic gonadotropin support of the corpus luteum during human gonadotropin therapy in women with anovulatory infertility. Fertil Steril 1988;50:31–35.Google Scholar
Lewit, N, Kol, S. The low responder female IVF patient with hypogonadotropic hypogonadism: do not give up! Fertil Steril 2000;74:401–402.CrossRefGoogle Scholar
Pandurangi, M, Tamizharasi, M, Reddy, NS. Pregnancy outcome of assisted reproductive technology cycle in patients with hypogonadotropic hypogonadism. J Hum Reprod Sci 2015;8:146–150.CrossRefGoogle ScholarPubMed
Durnerin, CI, Erb, K, Fleming, R, et al.; Luveris Pretreatment Group. Effects of recombinant LH treatment on folliculogenesis and responsiveness to FSH stimulation. Hum Reprod 2008;23:421–426.CrossRefGoogle ScholarPubMed
Sullivan, MW, Stewart-Akers, A, Krasnow, JS, Berga, SL, Zeleznik, AJ. Ovarian responses in women to recombinant follicle-stimulating hormone and luteinizing hormone (LH): a role for LH in the final stages of follicular maturation. J Clin Endocrinol Metab 1999;84:228–232.Google ScholarPubMed
Yong, EL, Baird, DT, Yates, R, Reichert, LE Jr., Hillier, SG. Hormonal regulation of the growth and steroidogenic function of human granulosa cells. J Clin Endocrinol Metab 1992;74:842–849.CrossRefGoogle ScholarPubMed
Loumaye, E, Engrand, P, Shoham, Z, Hillier, SG, Baird, DT. Clinical evidence for an LH ‘ceiling’ effect induced by administration of recombinant human LH during the late follicular phase of stimulated cycles in World Health Organization type I and type II anovulation. Hum Reprod 2003;18:314–322.CrossRefGoogle Scholar
Baird, DT. Is there a place for different isoforms of FSH in clinical medicine? IV. The clinician’s point of view. Hum Reprod 2001;16:1316–1318.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×